Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial

Table 3 TEAEs by number of administered lasmiditan doses

N		Number of doses	Mean number of TEAEs^a	Mean difference^b	95% confidence interval	Paired t-test	Wilcoxson signed rank test
TEAEs
Total doses ≥ 10	289	1st to 5th dose	2.86
Total doses ≥ 10	289	6th to 10th dose	2.10	0.758	0.371, 1.145	p ≤ 0.0001	p < 0.0001
Total doses ≥ 20	181	1st to 5th dose	2.84
		6th to 10th dose	2.07	0.768	0.226, 1.310	p = 0.0057	p = 0.0002
		11th to 15th dose	1.70	1.138	0.535, 1.741	p = 0.0003	p < 0.0001
		16th to 20th dose	1.61	1.227	0.613, 1.840	p = 0.0001	p < 0.0001
Visits with TEAEs			Mean number of visits with TEAEs	Mean difference^a	95% confidence interval	Paired t-test	Wilcoxson signed rank test
Total doses ≥ 10	289	1st to 5th dose	1.61
Total doses ≥ 10	289	6th to 10th dose	1.25	0.360	0.204, 0.516	p < 0.0001	p < 0.0001
Total doses ≥ 20	181	1st to 5th dose	1.59
		6th to 10th dose	1.29	0.304	0.097, 0.511	p = 0.0042	p = 0.0018
		11th to 15th dose	1.12	0.475	0.241, 0.709	p < 0.0001	p < 0.0001
		16th to 20th dose	1.04	0.547	0.315, 0.779	p < 0.0001	p < 0.0001

N number of patients in analysis population, n number in category, TEAEs treatment-emergent adverse events
^aMean number of TEAEs per lasmiditan dose interval
^bMean difference from 1st to 5th dose values to post-baseline

ISSN: 1129-2377